

# KYRGYZSTAN

Number of new cases

**7 266**

Number of deaths


**4 672**

Number of prevalent cases (5-year)

**16 883**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	3 328 129	3 400 141	6 728 270
<b>Incidence*</b>			
Number of new cancer cases	3 371	3 895	7 266
Age-standardized incidence rate	143.3	117.6	125.8
Risk of developing cancer before the age of 75 years (cum. risk %)	16.1	12.2	13.7
Top 3 leading cancers (ranked by cases)**	Stomach Lung Liver	Breast Cervix uteri Stomach	Stomach Breast Lung
<b>Mortality*</b>			
Number of cancer deaths	2 454	2 218	4 672
Age-standardized mortality rate	105.9	68.0	82.8
Risk of dying from cancer before the age of 75 years (cum. risk %)	12.4	7.6	9.6
Top 3 leading cancers (ranked by deaths)**	Stomach Lung Liver	Cervix uteri Breast Stomach	Stomach Lung Liver
<b>Prevalence*</b>			
5-year prevalent cases	6 857	10 026	16 883



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Stomach	640	19.0%
2nd	Lung	597	17.7%
3rd	Liver	273	8.1%
4th	Colorectum	220	6.5%
5th	Leukaemia	137	4.1%
-	Others	1 504	44.6%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	852	21.9%
2nd	Cervix uteri	479	12.3%
3rd	Stomach	292	7.5%
4th	Ovary	241	6.2%
5th	Corpus uteri	232	6.0%
-	Others	1 799	46.2%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Stomach	932	12.8%
2nd	Breast	852	11.7%
3rd	Lung	782	10.8%
4th	Cervix uteri	479	6.6%
5th	Colorectum	437	6.0%
-	Others	3 784	52.1%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Stomach	932	1	12.8	2.0	787	1	16.8	1.8	1 489	22.1
Breast	852	2	11.7	2.7	270	6	5.8	0.95	2 550	75.0
Lung	782	3	10.8	1.9	636	2	13.6	1.5	1 085	16.1
Cervix uteri	479	4	6.6	1.5	278	5	6.0	0.94	1 435	42.2
Colorectum	437	5	6.0	0.95	287	4	6.1	0.62	1 176	17.5
Liver	431	6	5.9	0.98	400	3	8.6	0.93	577	8.6
Pancreas	258	7	3.6	0.60	238	7	5.1	0.56	285	4.2
Brain CNS	245	8	3.4	0.40	188	8	4.0	0.33	863	12.8
Leukaemia	243	9	3.3	0.34	159	10	3.4	0.24	738	11.0
Ovary	241	10	3.3	0.83	156	11	3.3	0.57	657	19.3
Corpus uteri	232	11	3.2	0.80	79	13	1.7	0.31	766	22.5
Oesophagus	177	12	2.4	0.40	161	9	3.4	0.36	245	3.6
Kidney	144	13	2.0	0.31	99	12	2.1	0.23	404	6.0
Prostate	134	14	1.8	0.95	77	14	1.6	0.47	298	9.0
Bladder	121	15	1.7	0.28	59	16	1.3	0.14	351	5.2
Lip, oral cavity	106	16	1.5	0.20	70	15	1.5	0.14	276	4.1
Thyroid	104	17	1.4	0.18	22	22	0.47	0.05	330	4.9
NHL	97	18	1.3	0.19	59	16	1.3	0.11	301	4.5
Larynx	80	19	1.1	0.21	52	18	1.1	0.13	232	3.5
Gallbladder	57	20	0.78	0.15	31	19	0.66	0.08	82	1.2
Hodgkin lymphoma	52	21	0.72	0.06	16	25	0.34	0.03	180	2.7
Hypopharynx	49	22	0.67	0.10	22	22	0.47	0.05	91	1.4
Melanoma	43	23	0.59	0.07	23	21	0.49	0.04	132	2.0
Salivary glands	42	24	0.58	0.07	18	24	0.39	0.04	115	1.7
Nasopharynx	35	25	0.48	0.07	27	20	0.58	0.05	91	1.4
Vulva	34	26	0.47	0.10	13	28	0.28	0.04	96	2.8
Testis	28	27	0.39	0.06	9	29	0.19	0.03	99	3.0
Oropharynx	19	28	0.26	0.04	15	26	0.32	0.04	46	0.68
Multiple myeloma	16	29	0.22	0.04	14	27	0.30	0.04	42	0.62
Kaposi sarcoma	10	30	0.14	0.02	6	30	0.13	0.01	25	0.37
Vagina	9	31	0.12	0.05	5	31	0.11	0.02	21	0.62
Mesothelioma	4	32	0.06	0.01	4	32	0.09	0.01	6	0.09
<b>All cancers</b>	<b>7 266</b>	-	-	<b>13.7</b>	<b>4 672</b>	-	-	<b>9.6</b>	<b>16 883</b>	-
<b>All cancers excl. NMSC</b>	<b>7 040</b>	-	-	<b>13.4</b>	<b>4 622</b>	-	-	<b>9.5</b>	<b>16 257</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

